O	0	10	Randomized
O	10	11	,
O	12	19	placebo
O	19	20	-
O	20	30	controlled
O	31	36	trial
O	37	39	of
B-intervention	40	47	Saforis
O	48	51	for
O	52	62	prevention
O	63	66	and
O	67	76	treatment
O	77	79	of
O	80	84	oral
O	85	94	mucositis
O	95	97	in
B-eligibility	98	104	breast
I-eligibility	105	111	cancer
I-eligibility	112	120	patients
I-eligibility	121	130	receiving
I-eligibility	131	144	anthracycline
I-eligibility	144	145	-
I-eligibility	145	150	based
I-eligibility	151	163	chemotherapy
O	163	164	.

O	165	169	Oral
O	170	179	mucositis
O	180	181	(
O	181	183	OM
O	183	184	)
O	185	187	is
O	188	189	a
O	190	198	frequent
O	199	211	complication
O	212	214	of
O	215	224	mucotoxic
O	225	231	cancer
O	232	239	therapy
O	239	240	,
O	241	248	causing
O	249	260	significant
O	261	265	oral
O	266	270	pain
O	270	271	,
O	272	281	increased
O	282	291	infection
O	292	296	risk
O	296	297	,
O	298	301	and
O	302	310	impaired
O	311	322	functioning
O	322	323	.

O	324	327	The
O	328	336	efficacy
O	337	340	and
O	341	347	safety
O	348	350	of
O	351	358	Saforis
O	359	360	(
O	360	369	glutamine
O	369	370	)
O	371	377	powder
O	378	380	in
O	381	386	UpTec
O	387	390	for
O	391	395	oral
O	396	406	suspension
O	407	410	was
O	411	420	evaluated
O	421	424	for
O	425	428	the
O	429	439	prevention
O	440	443	and
O	444	453	treatment
O	454	456	of
O	457	459	OM
O	459	460	.

B-total-participants	461	466	Three
I-total-participants	467	474	hundred
I-total-participants	475	481	twenty
I-total-participants	481	482	-
I-total-participants	482	485	six
O	486	494	patients
O	495	505	developing
O	506	511	World
O	512	518	Health
O	519	531	Organization
O	532	533	(
O	533	536	WHO
O	536	537	)
O	538	543	grade
O	544	545	>
O	545	547	or
O	547	548	=
O	548	549	2
O	550	552	OM
O	553	559	during
O	560	561	a
O	562	574	chemotherapy
O	575	584	screening
O	585	590	cycle
O	591	595	were
O	596	606	randomized
O	607	609	to
O	610	617	Saforis
O	618	619	(
O	619	620	n
O	621	622	=
B-intervention-participants	623	626	163
O	626	627	)
O	628	630	or
B-control	631	638	placebo
O	639	640	(
O	640	641	n
O	642	643	=
B-control-participants	644	647	163
O	647	648	)
O	649	650	3
O	651	656	times
O	656	657	/
O	657	660	day
O	661	667	during
O	668	673	their
O	674	678	next
O	679	691	chemotherapy
O	692	697	cycle
O	698	699	(
O	699	708	Treatment
O	709	714	Cycle
O	715	716	1
O	716	717	)
O	717	718	.

O	719	727	Patients
O	728	732	were
O	733	740	crossed
O	741	745	over
O	746	748	to
O	749	752	the
O	753	762	alternate
O	763	772	treatment
O	773	779	during
O	780	789	Treatment
O	790	795	Cycle
O	796	797	2
O	797	798	.

O	799	801	As
O	802	814	prespecified
O	815	817	in
O	818	821	the
O	822	833	statistical
O	834	838	plan
O	838	839	,
O	840	847	because
O	848	850	of
O	851	852	a
O	853	862	carryover
O	863	869	effect
O	870	872	in
O	873	882	Treatment
O	883	888	Cycle
O	889	890	2
O	891	894	the
O	895	902	primary
O	903	911	efficacy
O	912	920	analysis
O	921	924	was
O	925	930	based
O	931	933	on
O	934	943	Treatment
O	944	949	Cycle
O	950	951	1
O	952	956	only
O	956	957	.

O	958	966	Compared
O	967	971	with
O	972	979	placebo
O	979	980	,
O	981	988	Saforis
O	989	1002	significantly
O	1003	1010	reduced
O	1011	1014	the
O	1015	1024	incidence
O	1025	1027	of
O	1028	1038	clinically
O	1039	1050	significant
B-outcome	1051	1054	WHO
I-outcome	1055	1060	grade
I-outcome	1061	1062	>
I-outcome	1062	1064	or
I-outcome	1064	1065	=
I-outcome	1065	1066	2
I-outcome	1067	1069	OM
O	1070	1071	(
B-iv-bin-percent	1071	1073	38
I-iv-bin-percent	1073	1074	.
I-iv-bin-percent	1074	1075	7
I-iv-bin-percent	1075	1076	%
O	1077	1079	vs
O	1079	1080	.
B-cv-bin-percent	1081	1083	49
I-cv-bin-percent	1083	1084	.
I-cv-bin-percent	1084	1085	7
I-cv-bin-percent	1085	1086	%
O	1086	1087	;
O	1088	1089	P
O	1090	1091	=
O	1092	1093	.
O	1093	1096	026
O	1096	1097	)
O	1098	1101	and
B-outcome	1102	1108	severe
I-outcome	1109	1112	WHO
I-outcome	1113	1118	grade
I-outcome	1119	1120	>
I-outcome	1120	1122	or
I-outcome	1122	1123	=
I-outcome	1123	1124	3
I-outcome	1125	1127	OM
O	1128	1129	(
B-iv-bin-percent	1129	1130	1
I-iv-bin-percent	1130	1131	.
I-iv-bin-percent	1131	1132	2
I-iv-bin-percent	1132	1133	%
O	1134	1136	vs
O	1136	1137	.
B-cv-bin-percent	1138	1139	6
I-cv-bin-percent	1139	1140	.
I-cv-bin-percent	1140	1141	7
I-cv-bin-percent	1141	1142	%
O	1142	1143	;
O	1144	1145	P
O	1146	1147	=
O	1148	1149	.
O	1149	1152	005
O	1152	1153	)
O	1154	1156	in
O	1157	1166	Treatment
O	1167	1172	Cycle
O	1173	1174	1
O	1174	1175	.

O	1176	1183	Saforis
O	1184	1188	also
O	1189	1202	significantly
O	1203	1210	reduced
O	1211	1214	the
B-outcome	1215	1220	worst
I-outcome	1221	1225	Oral
I-outcome	1226	1235	Mucositis
I-outcome	1236	1246	Assessment
I-outcome	1247	1252	Scale
I-outcome	1253	1263	ulceration
I-outcome	1264	1269	score
O	1270	1272	in
O	1273	1282	Treatment
O	1283	1288	Cycle
O	1289	1290	1
O	1291	1299	compared
O	1300	1304	with
O	1305	1312	placebo
O	1313	1314	(
O	1314	1318	mean
O	1318	1319	,
B-iv-cont-mean	1320	1321	0
I-iv-cont-mean	1321	1322	.
I-iv-cont-mean	1322	1324	23
O	1325	1326	+
O	1326	1327	/
O	1327	1328	-
B-iv-cont-sd	1329	1330	0
I-iv-cont-sd	1330	1331	.
I-iv-cont-sd	1331	1333	39
O	1334	1336	vs
O	1336	1337	.
B-cv-cont-mean	1338	1339	0
I-cv-cont-mean	1339	1340	.
I-cv-cont-mean	1340	1342	32
O	1343	1344	+
O	1344	1345	/
O	1345	1346	-
B-cv-cont-sd	1347	1348	0
I-cv-cont-sd	1348	1349	.
I-cv-cont-sd	1349	1351	45
O	1351	1352	;
O	1353	1354	P
O	1355	1356	=
O	1357	1358	.
O	1358	1361	013
O	1361	1362	)
O	1362	1363	.

O	1364	1372	Patients
O	1373	1382	receiving
O	1383	1390	Saforis
O	1391	1393	in
O	1394	1403	Treatment
O	1404	1409	Cycle
O	1410	1411	1
O	1412	1415	had
O	1416	1417	a
O	1418	1423	lower
O	1423	1424	-
O	1424	1428	than
O	1428	1429	-
O	1429	1437	expected
O	1438	1440	OM
O	1441	1450	incidence
O	1451	1455	when
O	1456	1463	crossed
O	1464	1468	over
O	1469	1471	to
O	1472	1479	placebo
O	1480	1482	in
O	1483	1492	Treatment
O	1493	1498	Cycle
O	1499	1500	2
O	1500	1501	,
O	1502	1512	indicating
O	1513	1514	a
O	1515	1526	significant
O	1527	1536	carryover
O	1537	1543	effect
O	1544	1545	(
O	1545	1546	P
O	1547	1548	=
O	1549	1550	.
O	1550	1553	027
O	1553	1554	)
O	1554	1555	.

O	1556	1559	The
O	1560	1569	incidence
O	1570	1572	of
O	1573	1582	treatment
O	1582	1583	-
O	1583	1591	emergent
B-outcome	1592	1599	adverse
I-outcome	1600	1606	events
O	1607	1610	was
O	1611	1618	similar
O	1619	1626	between
O	1627	1633	groups
O	1633	1634	.

O	1635	1642	Saforis
O	1643	1645	is
O	1646	1650	safe
O	1651	1654	and
O	1655	1664	effective
O	1665	1668	for
O	1669	1679	preventing
O	1680	1683	and
O	1684	1692	treating
O	1693	1695	OM
O	1696	1698	in
O	1699	1707	patients
O	1708	1717	receiving
O	1718	1727	mucotoxic
O	1728	1734	cancer
O	1735	1747	chemotherapy
O	1747	1748	.
